Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Vaccinations01:51

Vaccinations

Overview
Vaccines01:21

Vaccines

Vaccines are among the most effective tools in preventive medicine, designed to prepare the immune system to recognize and combat infectious agents. By introducing antigens—substances that the immune system identifies as foreign—vaccines stimulate an adaptive immune response that leads to immunological memory. This immunological memory enables the body to mount a faster and more effective response upon future exposures to the actual pathogen.Vaccines can be categorized based on the type of...
Immunodeficiency Diseases01:25

Immunodeficiency Diseases

Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency disorders...
Vaccine Production01:23

Vaccine Production

Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...
Development of Immunocompetence01:22

Development of Immunocompetence

The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
Healthcare Associated Infections II: Preventive Measures01:22

Healthcare Associated Infections II: Preventive Measures

Essential infection prevention measures are based on the knowledge of the infection chain, the modes of transmission in healthcare settings, and the use of the best practices in all healthcare settings. Compulsory public reporting of healthcare-associated infection rates is needed to allow individuals and the community to make informed choices regarding selecting a healthcare facility.
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Short-Term Safety and Adverse Event Risk Profiles for SARS-CoV-2 Booster Vaccine Doses in Australian Adults: A Survey Study.

The Medical journal of Australia·2026
Same author

Vaccine uptake in the context of mandate announcement and removal: Evidence from Europe and North America.

Vaccine·2026
Same author

Mpox disease epidemiology, vaccine uptake and vaccination coverage in Australia 2022-2024: a descriptive study.

EClinicalMedicine·2026
Same author

Annual immunisation coverage report 2024.

Communicable diseases intelligence (2018)·2026
Same author

ATAGI 2024 Annual Statement on Immunisation.

Communicable diseases intelligence (2018)·2026
Same author

ATAGI Targeted Review 2024: Immunisation strategies for prevention and control of respiratory syncytial virus disease in Australia.

Communicable diseases intelligence (2018)·2026
Same journal

Measles epidemiology in Australia: 2014 to 2024. Erratum to 10.33321/cdi.2026.50.016.

Communicable diseases intelligence (2018)·2026
Same journal

Presymptomatic transmission, vaccine breakthrough and anonymous contacts: a cluster of mpox in Canberra, Australian Capital Territory, 2024.

Communicable diseases intelligence (2018)·2026
Same journal

The Strategic Plan for Tuberculosis Elimination and Equity in Australia 2026-2030.

Communicable diseases intelligence (2018)·2026
Same journal

An atlas of common Salmonella serotypes from routinely notified human cases in the Northern Territory of Australia, 2005-2024.

Communicable diseases intelligence (2018)·2026
Same journal

Meningococcal Surveillance Australia: Reporting period 1 October to 31 December 2025.

Communicable diseases intelligence (2018)·2026
Same journal

Australian Gonococcal Surveillance Program, 1 October to 31 December 2025.

Communicable diseases intelligence (2018)·2026
See all related articles

Related Experiment Video

Updated: May 27, 2026

Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens
13:47

Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens

Published on: May 19, 2020

ATAGI 2025 Annual Statement on Immunisation.

Katrina Nicolopoulos1, Saskia van der Kooi2, Clayton Chiu3

  • 1National Centre for Immunisation Research and Surveillance, Children's Hospital at Westmead, Sydney, New South Wales, Australia.

Communicable Diseases Intelligence (2018)
|May 25, 2026
PubMed
Summary
This summary is machine-generated.

The Australian Technical Advisory Group on Immunisation (ATAGI) 2025 Annual Statement reviews 2024 vaccine successes and challenges. It provides priority advice for immunisation and vaccine-preventable disease control in Australia for 2025.

Keywords:
Australiaimmunisationvaccine preventable diseases

More Related Videos

Rapid In Vivo Assessment of Adjuvant's Cytotoxic T Lymphocytes Generation Capabilities for Vaccine Development
09:03

Rapid In Vivo Assessment of Adjuvant's Cytotoxic T Lymphocytes Generation Capabilities for Vaccine Development

Published on: June 19, 2018

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches
13:36

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches

Published on: May 6, 2015

Related Experiment Videos

Last Updated: May 27, 2026

Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens
13:47

Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens

Published on: May 19, 2020

Rapid In Vivo Assessment of Adjuvant's Cytotoxic T Lymphocytes Generation Capabilities for Vaccine Development
09:03

Rapid In Vivo Assessment of Adjuvant's Cytotoxic T Lymphocytes Generation Capabilities for Vaccine Development

Published on: June 19, 2018

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches
13:36

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches

Published on: May 6, 2015

Area of Science:

  • Public Health
  • Immunology
  • Epidemiology

Background:

  • The Australian Technical Advisory Group on Immunisation (ATAGI) releases its fifth annual statement.
  • This statement reviews the landscape of vaccine use and vaccine-preventable diseases (VPDs) in Australia during 2024.

Purpose of the Study:

  • To summarize key successes, trends, and challenges in Australian immunisation efforts in 2024.
  • To outline ATAGI's priority advice and recommended actions for 2025 and beyond.
  • To inform public health strategies for vaccine-preventable disease control.

Main Methods:

  • Review of national immunisation data and disease surveillance reports from 2024.
  • Analysis of trends in vaccine uptake and the epidemiology of VPDs.
  • Expert consultation and consensus-building within ATAGI.

Main Results:

  • Identification of significant achievements in vaccine administration and VPD control.
  • Characterization of emerging trends and persistent challenges in the immunisation program.
  • Specific data on the impact of vaccines on disease burden in Australia.

Conclusions:

  • ATAGI's 2025 statement provides critical insights into the state of immunisation in Australia.
  • The findings guide future public health interventions and policy development.
  • Proactive strategies are essential for sustained control of vaccine-preventable diseases.